Vaccines to prevent acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection elicit
an immune neutralizing response. Some concerns have been raised regarding the safety of …

Designing and manufacturing efficient vaccines against coronavirus disease 2019 (COVID‐
19) is a major objective. In this systematic review, we aimed to evaluate the most important …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the deadly
disease known as coronavirus disease 2019 (COVID-19) that has reached pandemic …

(1) Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines
were developed in only a short amount of time and were widely distributed. We conducted …

The Covid-19 epidemic continues to rage, especially in countries that have been unable or
unwilling to institute strong public health measures. A return to normality has increasingly …

A massive COVID-19 vaccination campaign is underway worldwide. Epidemiological data
from studies indicate excellent efficacy and safety profile for COVID-19 vaccines. However …

Since COVID‐19 took a strong hold around the globe causing considerable morbidity and
mortality, a lot of effort was dedicated to manufacturing effective vaccines against SARS …

Introduction Several vaccine candidates have been developed using different platforms,
including nucleic acids (DNA and RNA), viral vectors (replicating and non-replicating), virus …

The benefits of SARS-CoV-2 spike mRNA vaccines are well known, including a significant
decline in COVID-19 morbidity and a decrease in the mortality rate of SARS-CoV-2 infected …

Since the emergence of SARS-CoV-2 at the end of 2019, 64 candidate vaccines are in
clinical development and 173 are in the pre-clinical phase. Five types of vaccines are …